Crossmark

SER recommendations on the use of biological drugs in primary Sjögren's syndrome

Crossref DOI link: https://doi.org/10.1016/j.reumae.2018.10.017

Published Print: 2019-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Andréu Sánchez, José Luis

Fernández Castro, Mónica

Díaz del Campo Fontecha, Petra

Corominas, Héctor

Narváez García, Francisco Javier

Rosas Gómez de Salazar, José

Rua-Figueroa, Íñigo

Abad Hernández, Miguel Ángel

Álvarez Rivas, María Noelia

del Pino Montes, Javier

Francisco Hernández, Félix Manuel

Gantes Pedraza, María Ángeles

Greco Merino, Martín Gerardo

Hernández, María Vanesa

Navarro Compán, María Victoria

Solarte, Juan Alberto Paz

Romero Bueno, Fredeswinda I.

Park, Hye Sang

Sivera Mascaró, Francisca

Rivas, María Noelia Álvarez

Montes, Javier del Pino

Pedraza, María Ángeles Gantes

Merino, Martín Gerardo Greco

Hernández, María Vanesa

Solarte, Juan Alberto Paz

Bueno, Fredeswinda I. Romero

Park, Hye Sang

Abad Hernández, Miguel Ángel

Hernández, Félix Manuel Francisco

Compán, María Victoria Navarro

Mascaró, Fran Sivera
Funding

Funding for this research was provided by:

Spanish Rheumatology Foundation
License Information

Text and Data Mining valid from 2019-11-01
More Information

This article is maintained by: Elsevier

Article Title: SER recommendations on the use of biological drugs in primary Sjögren's syndrome

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2018.10.017

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.reuma.2018.10.014

Content Type: article

Copyright: © 2018 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Document is current

Any future updates will be listed below